menubarKalispell Regional Healthcare

Kalispell Regional Healthcare

Open to Enrollment Studies

KRH Default

Cancer

To learn more or enroll in the following studies, contact Glacier View Research Institute-Cancer.

BREAST CANCER COLLABORATIVE REGISTRY
This registry will provide core support services for future multidisciplinary research on breast cancer and other chronic diseases.
Principal investigator: Melissa Hulvat

KEYNOTE 407
MK-3475-407-00
A randomized, double-blind, phase III study of carboplatin-paclitaxel/nab-paclitaxel chemotherapy with or without pembrolizumab (MK-3475) in first line metastatic squamous non-small cell lung cancer subjects.
Principal investigator: Elise Anderes

MIRACA
A registry of hematopoietic disease for evaluation and correlation with clinical outcomes.
Principal investigator: Peter Wagner

Cardiology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Cardiology.

ADVENT-HF
A multicenter, randomized study to assess the effects of adaptive servo-ventilation on survival and frequency of cardiovascular hospital admissions in patients with heart failure and sleep apnea.
Principal investigator: Anthony Dal Nogare

ARTESIA
Apixaban for the reduction of thromboembolism in patients with device-detected subclinical atrial fibrillation.
Principal investigator: Eve Gillespie

CLEAR
A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.
Principal investigator: Eve Gillespie

ONCOCYTE
A study to evaluate a panel of blood biomarkers for use in patients undergoing evaluation for lung cancer, ONC-LN-04.
Principal investigator: Katarina Egressy

PANTHEON
A multicenter, randomized, placebo-controlled, parallel group, double-blind, dose-finding phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction.
Principal investigator: Eve Gillespie

Endocrinology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Endocrinology.

BEST
A double-blind, placebo-controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with Type 2 diabetes and increased risk of cardiovascular adverse events.
Principal investigator: Jose de Souza

NN1250-4252
A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with Type 2 diabetes mellitus inadequately treated with basal insulin and oral antidiabetic drugs.
Principal investigator: Jose de Souza

PROMINENT
Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes.
Principal investigator: Jose de Souza

Pain Management

There are no open studies at this time.

Rheumatology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Rheumatology.

CREDO 2
A randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter phase III study of the efficacy and safety of olokizumab in subjects with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate therapy.
Principal investigator: Roger Diegel

CREDO 3
A randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study of the efficacy and safety of olokizumab in subjects with moderately to severely active rheumatoid arthritis inadequately controlled by tumor necrosis factor alpha inhibitor therapy.
Principal investigator: Roger Diegel

HGS/GSK
A randomized, double-blind, placebo-controlled 52-week study to assess adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus receiving belimumab.
Principal investigator: Roger Diegel

LILLY RHBV
A multicenter, randomized, double-blind, active and placebo-controlled 16-week study followed by long term evaluation of efficacy and safety of ixekizumab (LY2439821) in bDMARD-naive patients with radiographic axial spondyloarthritis.
Principal investigator: Roger Diegel

LILLY RHBX
A 52-week multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ixekizumab (LY2439821) in bDMARD-naive patients with nonradiographic axial spondyloarthritis.
Principal investigator: Roger Diegel

PFIZER
Phase 3b/4 randomized safety endpoint study of two doses of tofacitinib in comparison to a tumor necrosis factor inhibitor in subjects with rheumatoid arthritis.
Principal investigator: Roger Diegel